Description Proton pump inhibitors (PPIs) are among the most commonly used medications
in the world. Developed for the treatment and prevention of acid-mediated upper …

Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy for upper
gastrointestinal disorders, including gastroesophageal reflux disease, dyspepsia, and peptic …

Abstract Background Neuroendocrine tumors (NETs) are a form of cancer that differ from
other neoplasia in that they synthesize, store, and secrete peptides, eg, chromogranin A …

Recent milestones in the understanding of gastric acid secretion and treatment of acid-
peptic disorders include the (1) discovery of histamine H2-receptors and development of …

Context Patients discharged from acute care hospitals may be at risk for unintentional
discontinuation of medications prescribed for chronic diseases. The intensive care unit (ICU) …

BACKGROUND & AIMS: Rebound acid hypersecretion (RAHS) has been demonstrated
after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related …

Owing to the heterogeneity of neuroendocrine neoplasms (NENs), the availability of reliable
circulating markers is critical for improving diagnostics, prognostic stratification, follow-up …

Gastro-oesophageal reflux disease (GORD) develops when reflux of gastric content causes
troublesome symptoms or complications. The main symptoms are heartburn and acid …

OBJECTIVES: Conflicting data exist on whether discontinuation of proton pump inhibitors
(PPIs) is associated with rebound secretion of gastric acid. METHODS: A total of 48 …

Background: There have been concerns raised about the potential adverse effects of proton
pump inhibitors, especially with long‐term use. In particular, their potent action can suppress …